CytomX Therapeutics unveils advances in masked oncology therapeutics and pipeline progress
I'm PortAI, I can summarize articles.
CytomX Therapeutics Inc. presented updates on its oncology pipeline at the 44th Annual JP Morgan Healthcare Conference, focusing on its PROBODY® platform for targeted cancer treatment. Key programs include varsetatug masetecan (Varseta-M) for colorectal cancer and CX-801 for melanoma. The company plans additional studies and collaborations with major firms, and reported a cash runway extending into Q2 2027. The full presentation is accessible via a provided link.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments